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Background
The A1 adenosine receptor is a member of the rhodopsin-
related subfamily of GPCRs. Point mutations in the con-
served NPxxY(x)5,6F motif at the junction of helix 7 and
the C-terminus disrupt surface targeting of the receptor
and result in its intracellular retention. This trafficking
arrest can be overcome by addition of receptor ligands
(pharmacochaperoning) that stabilize the receptor fold
and thus promote surface expression. The mutants serve
as a tool to explore a ramification of the retaliatory meta-
bolite complex: hypoxia leads to intracellular accumulation
of adenosine (by breakdown of ATP and by inhibition of
adenosine kinase). Intracellular and extracellular adeno-
sine levels are in equilibrium because of the action of the
equilibrative nucleoside transporters. Extracellular adeno-
sine dampens cellular metabolism by acting on inhibitory
A1 adenosine receptors and thus counteracts the impact of
hypoxia. If adenosine also pharmacochaperoned A1 adeno-
sine receptors during hypoxia, it would enhance its effec-
tiveness as a protective agent.
Methods
We created cell lines that stably expressed A1 receptor
Y288A with either a C-terminal YFP or an N-terminal
FLAG-epitope fused to a streptactin peptide. These cell
lines were incubated with a combination of inhibitors to
test whether manipulations of intracellular adenosine
levels increased the accumulation of the receptor. The A1
antagonist DPCPX was used as an internal control. To
mimic hypoxia, the cells were incubated for 24 hours
under 5% O2 content conditions. Radioligand binding and
Western blotting was performed to determine the level of
mature, binding competent receptors.
Results
Inhibition of adenosine kinase, adenosine deaminase and
equilibrative nucleoside transporters enhanced the accu-
mulation of binding competent receptors. The action of
these inhibitors was as effective as DPCPX in pharmaco-
chaperoning the receptor. The receptors acquired a
mature glycosylation status indicative of export from the
ER and delivery to the Golgi, and they reached the cell
surface. Moreover, the action of the enzyme inhibitor
cocktail could also be elicited by hypoxia.
Conclusions
Accumulation of intracellular adenosine elicits a phar-
macochaperoning effect. Accordingly, the retaliatory
metabolite concept may be extended to include a phar-
macochaperoning (“physiochaperoning”) action of
adenosine.
Acknowledgements
This work was supported by the Austrian Sciences Fund (FWF) and the
Medical University of Vienna.
Published: 17 September 2012
doi:10.1186/2050-6511-13-S1-A63
Cite this article as: Kusek et al.: Pharmacochaperoning of the ER-
retained A1 adenosine receptor. BMC Pharmacology and Toxicology 2012
13(Suppl 1):A63.
* Correspondence: michael.freissmuth@meduniwien.ac.at
Institute of Pharmacology, Center for Physiology and Pharmacology, Medical
University of Vienna, 1090 Vienna, Austria
Kusek et al. BMC Pharmacology and Toxicology 2012, 13(Suppl 1):A63
http://www.biomedcentral.com/2050-6511/13/S1/A63
© 2012 Kusek et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
